{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:24:38Z","timestamp":1794511478333,"version":"4.9.1"},"reference-count":108,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,4,13]]},"DOI":"10.1080\/14656566.2026.2662949","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:22:48Z","timestamp":1776792168000},"page":"531-544","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapeutic landscape for the management of agitation associated with Alzheimer\u2019s disease"],"prefix":"10.1080","volume":"27","author":[{"given":"Samir","family":"Jain","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece Buyuksandalyaci","family":"Tunc","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70235"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.07.001"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01294-2"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.644317"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01210-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.4363"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220508"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02227-4"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2024.2363215"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610214001963"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610222001041"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.173501"},{"issue":"9","key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.NAJ.0000978132.65971.f6","article-title":"First drug to treat agitation associated with Alzheimer\u2019s dementia","volume":"123","author":"Aschenbrenner DS.","year":"2023","unstructured":"Aschenbrenner DS. First drug to treat agitation associated with Alzheimer\u2019s dementia. Am J Nurs [Internet]. 2023;123(9):20\u201321.","journal-title":"Am J Nurs"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924000427"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2015.05.005"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.04.013"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12915"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2020.10.011"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000095"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-025-05719-w"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13670-019-0269-1"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00910"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013304.pub2"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv055"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0586"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.200"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1476140"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.8522"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105173"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07576-8"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.09.009"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14282"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720507779939805"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0555-y"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12157"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.946"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035663"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117744996"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-022-00992-5"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_3_4_45_1","unstructured":"U.S. FDA Drug Safety Communication. Citalopram dose-related qt prolongation\/torsade risk; max dose recommendations. 2011."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.7124"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03569-y"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101362"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-231167"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5381"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22662.1"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101362"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.12.005"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1103039"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008191.pub2"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317514524813"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066583"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1667"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2006.07.006"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035185"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610213000239"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2014.11.002"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.582484"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12754"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-199700540-00010"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200307000-00006"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720505774932205"},{"issue":"11","key":"e_1_3_4_68_1","first-page":"942","article-title":"Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial","volume":"13","author":"Tariot PN","year":"2005","unstructured":"Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13(11):942\u2013949.","journal-title":"Am J Geriatr Psychiatry"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1159\/000097757"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.72"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub4"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02529.x"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.54"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200111000-00008"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1159\/000199236"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3310\/VPDT7105"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181ca0c59"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02586-y"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2136162"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2195539"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610212002141"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01133-9"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL-.0000000000205634"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01780-0"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.24nr03737"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10214"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.324842"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1267726"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1081"},{"key":"e_1_3_4_90_1","unstructured":"AXS-05 - axsome Therapeutics [Internet]. Available from: https:\/\/www.axsome.com\/axs-portfolio\/pipeline\/about-axs-05\/"},{"key":"e_1_3_4_91_1","unstructured":"Axsome therapeutics announces FDA acceptance and priority review of supplemental New drug application for AXS-05 for the treatment of Alzheimer\u2019s disease agitation. 2025 [cited 2026 Feb 25]."},{"key":"e_1_3_4_92_1","unstructured":"A study to assess the efficacy and safety of AXS-05 in subjects with Alzheimer\u2019s disease agitation (NCT05557409) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05557409"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.05.002"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.plunaro2417ah"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-2262-7837"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619846993"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2021.01.015"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19196"},{"key":"e_1_3_4_99_1","unstructured":"Grossberg G. BioXcel Therapeutics announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of Alzheimer\u2019s disease-related agitation. 2023."},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181ab8c61"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000414"},{"issue":"1","key":"e_1_3_4_102_1","first-page":"e12307","article-title":"Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer\u2019s disease: a randomized, double-blind, phase 2, proof-of-concept study","volume":"8","author":"Nirogi R","year":"2022","unstructured":"Nirogi R, Ieni J, Goyal VK, et al. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer\u2019s disease: a randomized, double-blind, phase 2, proof-of-concept study. Alzheimer\u2019s Dement Transl ResearchClin Interv. 2022;8(1):e12307.","journal-title":"Alzheimer\u2019s Dement Transl ResearchClin Interv"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5813"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209065"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00155-8"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00001"},{"key":"e_1_3_4_108_1","unstructured":"Study details | NCT07011745 | a phase 3 study to evaluate the safety and efficacy of KarXT + KarX-EC for the treatment of agitation associated with Alzheimer\u2019s disease (ADAGIO-2) | ClinicalTrials.gov [Internet]. 2025 [updated 2026 Apr 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07011745?term=ADAGIO-2&rank=1"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13844"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2025.105485"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2662949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:54:28Z","timestamp":1778763268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2662949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,4,13]]}},"alternative-id":["10.1080\/14656566.2026.2662949"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2662949","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}